Publications by authors named "Gyeonghoon Kim"
A multicenter, double-blind, randomized, parallel-group, active-controlled, phase 3 clinical trial to compare the effectiveness and safety of two botulinum toxin type A formulations for improving moderate to severe glabellar wrinkles in Asians.
Sun Young Choi Young Gue Koh Yang Won Lee Hyung Seok Son Yi Na Yoon Gyeonghoon Kim Eun-Kyoung Kim Beom Joon Kim
J Dermatolog Treat
December 2024
Article Synopsis
- Botulinum toxin type A (BoNT-A), developed for wrinkle treatment, has a new formulation called BMI2006, evaluated in a phase 3 clinical trial involving 276 subjects.
- The trial showed that BMI2006 is as effective as the existing treatment, onabotulinumtoxin A (OBoNT), in reducing glabellar wrinkles after 4 weeks, with both groups reporting high satisfaction.
- Safety analysis revealed only mild and temporary side effects, confirming that BMI2006 is a safe option for treating wrinkles with effects lasting 8 to 12 weeks.
Article Synopsis
- Cold atmospheric plasma (CAP) shows potential as a treatment for malignant tumors, specifically melanoma and colon cancer, by significantly reducing cancer cell viability while sparing normal human cells.
- CAP combined with EGFR inhibitors leads to enhanced anticancer effects, particularly in resistant melanoma cell lines.
- In mouse models, CAP treatment effectively reduced tumor volume and weight, demonstrating its tumoricidal properties dependent on the treatment duration and frequency.
Background And Aims: Genome-wide association studies [GWAS] of inflammatory bowel disease [IBD] in multiple populations have identified over 240 susceptibility loci. We previously performed a largest-to-date Asian-specific IBD GWAS to identify two new IBD risk loci and confirm associations with 28 established loci. To identify additional susceptibility loci in Asians, we expanded our previous study design by doubling the case size with an additional dataset of 1726 cases and 378 controls.
View Article and Find Full Text PDF